Literature DB >> 15193535

Nefopam blocks voltage-sensitive sodium channels and modulates glutamatergic transmission in rodents.

Marc Verleye1, Nathalie André, Isabelle Heulard, Jean-Marie Gillardin.   

Abstract

In order to specify the nature of interactions between the analgesic compound nefopam and the glutamatergic system, we examined the effects of nefopam on binding of specific ligands on the three main subtypes ionotropic glutamate receptors: N-methyl-D-aspartate (NMDA), alpha-amino-3-hydroxy-5-methylisoxazole-4-propionic acid (AMPA), or quisqualic acid (QA) and kainic acid (KA) in rat brain membrane preparations. Functionally, we investigated the effects of nefopam against the seizures induced by agonists of these excitatory glutamate receptors in mice. Since the synaptic release of glutamate mainly depends upon the activation of membrane voltage-sensitive sodium channels (VSSCs), the nature of interactions between nefopam and these ionic channels was studied by evaluating the effects of nefopam on binding of 3H-batrachotoxinin, a specific ligand of the VSSCs in rat brain membrane preparations. The functional counterpart of the binding of nefopam on VSSCs was evaluated by its effects on the 22Na uptake-stimulated by veratridine on human neuroblastoma cells and in the maximal electroshock test in mice. Nefopam showed no affinity for the subtypes of ionotropic glutamate receptors up to 100 microM. On the other hand, nefopam was effective against NMDA, QA and KA induced clonic seizures in mice. Nefopam displaced 3H-batrachotoxinin and inhibited the uptake of 22Na in the micromolar range and it protected mice against electroshock induced seizures. Nefopam may block the VSSCs activity: consequently, at the presynaptic level, this effect led to a reduction of glutamate release and at the postsynaptic level, it led to a decrease of the neuronal excitability following activation of the glutamate receptors.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15193535     DOI: 10.1016/j.brainres.2004.04.035

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  29 in total

1.  Identifying mechanism-of-action targets for drugs and probes.

Authors:  Elisabet Gregori-Puigjané; Vincent Setola; Jérôme Hert; Brenda A Crews; John J Irwin; Eugen Lounkine; Lawrence Marnett; Bryan L Roth; Brian K Shoichet
Journal:  Proc Natl Acad Sci U S A       Date:  2012-06-18       Impact factor: 11.205

2.  Comparison Between Preoperative and Intraoperative Administration of Nefopam for Acute and Chronic Postoperative Pain in Colon Cancer Patients: A Prospective, Randomized, Double-Blind Study.

Authors:  Hyungsun Lim; Sehrin Kang; Boram Kim; Seonghoon Ko
Journal:  World J Surg       Date:  2019-12       Impact factor: 3.352

3.  The Effect of Intraoperative Nefopam Administration on Acute Postoperative Pain and Chronic Discomfort After Robotic or Endoscopic Assisted Thyroidectomy: A Randomized Clinical Trial.

Authors:  B G Kim; J Y Moon; J Y Choi; I S Park; A Y Oh; Y T Jeon; J W Hwang; J H Ryu
Journal:  World J Surg       Date:  2018-07       Impact factor: 3.352

4.  Status epilepticus caused by nefopam.

Authors:  Yong-Sook Park; Young-Baeg Kim; Jeong-Min Kim
Journal:  J Korean Neurosurg Soc       Date:  2014-11-30

Review 5.  The protective effect of chemical and natural compounds against vincristine-induced peripheral neuropathy (VIPN).

Authors:  Mitra Khodaei; Soghra Mehri; Soroush Rashid Pour; Shakiba Mahdavi; Fatemeh Yarmohammadi; A Wallace Hayes; Gholamreza Karimi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2022-05-14       Impact factor: 3.195

6.  Intraoperative Nefopam Reduces Acute Postoperative Pain after Laparoscopic Gastrectomy: a Prospective, Randomized Study.

Authors:  Hyo-Seok Na; Ah-Young Oh; Jung-Hee Ryu; Bon-Wook Koo; Sun-Woo Nam; Jihoon Jo; Jae-Hee Park
Journal:  J Gastrointest Surg       Date:  2018-01-26       Impact factor: 3.452

Review 7.  Recent advances in the pharmacological management of pain.

Authors:  Josée Guindon; Jean-Sébastien Walczak; Pierre Beaulieu
Journal:  Drugs       Date:  2007       Impact factor: 9.546

8.  A high throughput screen identifies Nefopam as targeting cell proliferation in β-catenin driven neoplastic and reactive fibroproliferative disorders.

Authors:  Raymond Poon; Helen Hong; Xin Wei; James Pan; Benjamin A Alman
Journal:  PLoS One       Date:  2012-05-30       Impact factor: 3.240

9.  Antinociceptive effect of intrathecal nefopam and interaction with morphine in formalin-induced pain of rats.

Authors:  Soo Young Cho; A Reum Park; Myung Ha Yoon; Hyung Gon Lee; Woong Mo Kim; Jeong Il Choi
Journal:  Korean J Pain       Date:  2013-01-04

10.  Mechanical Antiallodynic Effect of Intrathecal Nefopam in a Rat Neuropathic Pain Model.

Authors:  Kyung-Hoon Kim; Gyeong-Jo Byeon; Hee-Young Kim; Seung-Hoon Baek; Sang-Wook Shin; Sung-Tae Koo
Journal:  J Korean Med Sci       Date:  2015-07-15       Impact factor: 2.153

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.